Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 766

  • Showing results for elisaf. Search instead for elissaf (1 item)
1.

Arterial damage and cognitive decline in chronic kidney disease patients.

Karasavvidou D, Boutouyrie P, Kalaitzidis R, Kettab H, Pappas K, Stagikas D, Antonakis N, Tsalikakis D, Elisaf M, Laurent S.

J Clin Hypertens (Greenwich). 2018 Jul 14. doi: 10.1111/jch.13350. [Epub ahead of print]

2.

Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?

Filippatos TD, Christopoulou EC, Elisaf MS.

Curr Opin Lipidol. 2018 Aug;29(4):333-339. doi: 10.1097/MOL.0000000000000523.

PMID:
29994840
3.

Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study.

Ferrières J, Lautsch D, Ambegaonkar BM, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Velkovski-Rouyer M, Horack M, Almahmeed W, Chiang FT, Poh KK, Elisaf M, Brudi P, Gitt AK.

Int J Cardiol. 2018 Jun 6. pii: S0167-5273(18)30059-7. doi: 10.1016/j.ijcard.2018.06.008. [Epub ahead of print]

4.

SGLT2 inhibitors and the kidney: Effects and mechanisms.

Tsimihodimos V, Filippatos TD, Elisaf MS.

Diabetes Metab Syndr. 2018 Jun 6. pii: S1871-4021(18)30208-X. doi: 10.1016/j.dsx.2018.06.003. [Epub ahead of print] Review.

PMID:
29909004
5.

Treatment of Hypertension in Chronic Kidney Disease.

Kalaitzidis RG, Elisaf MS.

Curr Hypertens Rep. 2018 Jun 11;20(8):64. doi: 10.1007/s11906-018-0864-0. Review.

PMID:
29892833
6.

Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS).

Ferrières J, Lautsch D, Gitt AK, De Ferrari G, Toplak H, Elisaf M, Drexel H, Horack M, Baxter C, Ambegaonkar B, Brudi P, Toth PP.

Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13415. [Epub ahead of print]

PMID:
29888459
7.

Diagnostic lipid changes in patients with visceral leishmaniasis.

Tsimihodimos V, Kei A, Apostolou F, Elisaf M.

Hosp Pract (1995). 2018 Jun 6:1-4. doi: 10.1080/21548331.2018.1483171. [Epub ahead of print]

PMID:
29848097
8.

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions.

Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J, Redon P, Nilsson PM, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Grassi G.

J Hypertens. 2018 Jul;36(7):1441-1455. doi: 10.1097/HJH.0000000000001731.

PMID:
29652731
9.

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment.

Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Redon J, Redon P, Antza C, Tsioufis K, Grassi G, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Nilsson PM.

J Hypertens. 2018 Jul;36(7):1427-1440. doi: 10.1097/HJH.0000000000001730.

PMID:
29634663
10.

Novel Hypolipidaemic Drugs: Mechanisms Of Action And Main Metabolic Effects.

Filippatos TD, Liontos A, Christopoulou EC, Elisaf MS.

Curr Vasc Pharmacol. 2018 Feb 8. doi: 10.2174/1570161116666180209112351. [Epub ahead of print]

PMID:
29424317
11.

Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials.

Filippatos TD, Panagiotopoulou T, Tzavella E, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2018 May;23(3):187-191. doi: 10.1177/1074248418757011. Epub 2018 Feb 7.

PMID:
29409336
12.

Non-hemorrhage-related adverse effects of rivaroxaban.

Christopoulou EC, Filippatos TD, Elisaf MS.

Arch Med Sci Atheroscler Dis. 2017 Dec 31;2:e108-e112. doi: 10.5114/amsad.2017.72533. eCollection 2017.

13.

Effects of evolving lipid-lowering drugs on carbohydrate metabolism.

Tsimihodimos V, Elisaf M.

Diabetes Res Clin Pract. 2018 Mar;137:1-9. doi: 10.1016/j.diabres.2017.12.012. Epub 2017 Dec 24. Review.

PMID:
29278710
14.

Uric acid and cardiovascular risk: What genes can say.

Kei A, Koutsouka F, Makri A, Elisaf M.

Int J Clin Pract. 2018 Jan;72(1). doi: 10.1111/ijcp.13048. Epub 2017 Dec 18. Review.

PMID:
29250870
15.

No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study.

Makariou SE, Elisaf M, Challa A, Tentolouris N, Liberopoulos EN.

Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e52-e60. doi: 10.5114/amsad.2017.70504. eCollection 2017.

16.

Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study.

Filippatos TD, Liberopoulos E, Georgoula M, Tellis CC, Tselepis AD, Elisaf M.

Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e46-e51. doi: 10.5114/amsad.2017.70502. eCollection 2017.

17.

Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.

Rizos CV, Filippatos TD, Elisaf MS.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):117-125. doi: 10.1080/17425255.2018.1418325. Epub 2017 Dec 19. Review.

PMID:
29241374
18.

Hyponatremia in the elderly: challenges and solutions.

Filippatos TD, Makri A, Elisaf MS, Liamis G.

Clin Interv Aging. 2017 Nov 14;12:1957-1965. doi: 10.2147/CIA.S138535. eCollection 2017. Review.

19.

Serum Potassium Levels and Mortality in Acute Myocardial Infarction: Myth or Fact?

Barkas F, Elisaf M.

Angiology. 2017 Jan 1:3319717739721. doi: 10.1177/0003319717739721. [Epub ahead of print] No abstract available.

PMID:
29108419
20.

Effects of incretin-based therapies on renal function.

Tsimihodimos V, Elisaf M.

Eur J Pharmacol. 2018 Jan 5;818:103-109. doi: 10.1016/j.ejphar.2017.10.049. Epub 2017 Oct 21. Review.

PMID:
29066413

Supplemental Content

Loading ...
Support Center